In addition to concise and accurate presentation of supporting scientific data, value for money is a key criteria in drug subsidy or reimbursement decisions. This includes cost effectiveness and added value from comparative effectiveness research (CER). There is increasing requirement for manufacturers to demonstrate the pharmacoeconomic value of their products.